Heron Therapeutics Files 8-K

TL;DR

HRTX filed an 8-K today, likely containing regulatory disclosures or financial updates.

AI Summary

On December 23, 2024, Heron Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Heron Therapeutics is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

• Heron Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• 001-33221 (commission_file_number) — SEC File Number
• 94-2875566 (irs_number) — I.R.S. Employer Identification No.
• 100 Regency Forest Drive, Suite 300, Cary, NC 27518 (address) — Principal executive offices
• (858) 251-4400 (phone_number) — Registrant's telephone number
• 4242 Campus Point Court, Suite 200, San Diego, CA 92121 (address) — Business address
• AP PHARMA INC /DE/ (company) — Former company name
• ADVANCED POLYMER SYSTEMS INC /DE/ (company) — Former company name

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M

Filing Documents

• hrtx-20241223.htm (8-K) — 60KB
• hrtx-ex99_1.htm (EX-99.1) — 9KB
• 0000950170-24-139569.txt ( ) — 219KB
• hrtx-20241223.xsd (EX-101.SCH) — 49KB
• hrtx-20241223_htm.xml (XML) — 6KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 23, 2024, Heron Therapeutics, Inc. issued a press release announcing the relocation of its corporate headquarters from San Diego, California to Cary, North Carolina. Such press release is attached hereto and furnished as Exhibit 99.1. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: December 23, 2024 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR